An antibody treatment that delivers a targeted dose of chemotherapy directly to cancer cells shrank tumors in advanced ovarian cancer patients, achieving the primary goal in a late-stage clinical trial, the treatment’s maker, Immunogen, said Tuesday.
Based on the study outcome, Immunogen plans to submit the treatment — a so-called antibody drug conjugate — for accelerated approval with the Food and Drug Administration in early 2022. If cleared, it would be the 40-year-old company’s first wholly owned cancer medicine to reach the market.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
